Please login to the form below

Not currently logged in
Email:
Password:

Roche buys Memory Pharmaceuticals for $50m

Roche has signed a deal to acquire biopharmaceutical company Memory in a cash deal worth around $50m

Roche has signed a deal to acquire biopharmaceutical company Memory in a cash deal worth around $50m.

Memory develops drugs for central nervous system (CNS) disorders such as Alzheimer's and schizophrenia. The company currently has drug candidates in these areas undergoing clinical trials in partnership with Roche.

"Acquiring Memory will enable Roche to secure the future development of its promising nicotinic alpha-7 agonists," said William Burns, CEO Division Roche Pharmaceuticals. "The innovative work carried out by the scientists at Memory will be fully integrated into Roche's R&D portfolio with the aim of providing new hope for patients and caregivers affected by devastating diseases such as Alzheimer's."

Jonathan Fleming, chairman of the board of directors of Memory said: "Since founding Memory in 1998, we have focused on developing medicines that could make a real difference to the lives of CNS patients. I am proud of the progress our dedicated team has made and I am confident that Roche's capabilities and experience in the CNS field will enable our research to realise its full potential."

Under the terms of the merger agreement, Roche will tender an offer to acquire all outstanding shares of Memory at a 319 per cent premium to their closing price on November 24, 2008. The closing of the tender is subject to Roche holding a majority share once its acquired shares are added to its existing shares.

25th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...

Infographics